Oculeve
AcquiredSan Francisco · Founded 2011
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 2011
- Business Model
- B2B
- Last Round
- Series BMar 2014
- Rounds
- 3
About
Oculeve was a medical device company that developed TrueTear, a first-in-class non-invasive nasal neurostimulation device that activates the nasolacrimal pathway to stimulate natural tear production in patients with dry eye disease. Founded out of Stanford Biodesign, the company raised $24M before being acquired by Allergan in 2015 for $125 million upfront. The TrueTear device received FDA clearance and commercialized under Allergan.
Summary
Oculeve is a Biotech company based in San Francisco, founded in 2011. Its most recent funding was a Series B round in Mar 2014. Investors include Kleiner Perkins, Allergan and New Enterprise Associates.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2015
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.